pharmaphorum1d
Lynparza boosts long-term survival in early breast cancer
AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...
Hosted on MSN3d
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...
pharmaphorum3d
MSD gets first positive trial of Keytruda/Lynparza combo
"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...
FiercePharma4d
Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain'
Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...
Cure Today2d
Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer
Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.
GlobalData on MSN3d
MSD’s trial of combination therapy for ovarian cancer meets primary endpoint
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...
AstraZeneca, Merck report positive long-term data for Lynparza
AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...
The Pharma Letter2d
Lynparza on a roll with early breast cancer win
Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...
AstraZeneca says 87.5% of Lynparza-treated patients alive at six years in trial
Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...
Yahoo Finance3d
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
RAHWAY, N.J., December 11, 2024--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United ...
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...